Sinopharm Technology Co., Ltd. (08156) announced interim results for the six months ended December 31, 2023. The group took...
According to the Zhitong Finance App, Sinopharm Technology Co., Ltd. (08156) announced interim results for the six months ended December 31, 2023. The group obtained revenue of HK$18.84 million, an increase of 25.42% over the previous year; the company's equity holders should have accounted for a loss of HK$2,876 million, with a profit of HK$15.408 million for the same period last year; a basic loss of HK1.57 cents per share.
During the review period, the Group continued to accelerate its layout in the health industry. Through the establishment of subsidiaries in China, the Group completed the relevant layout for the development and distribution of proprietary Chinese medicines and health products, providing the Group with new revenue sources and business development directions. The Group continued to develop in the supply chain business under the “Internet +” service and achieved steady development during the review period. The Group is also discussing cooperation models with various industry operators and product suppliers to provide value-added services to operators in various industries through the Group's experience in the “Internet +” business. This brings new opportunities to the Group in the “Internet +” business and marks the acceleration of the Group's application to different business models in the “Internet +” business.